Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 156

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 1B
Chunk 156
---
 basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ WithumSmith+Brown, PC

We served as the Company's auditor from 2014 to 2024.

San Francisco, California

March 7, 2024

Except for Note 15, as to which the date is 

March 10, 2025

PCAOB ID Number 100

96

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)

    December 31, 2024

    December 31, 2023

    ASSETS

    CURRENT ASSETS

    Cash and cash equivalents
     
    $
    45,789

    $
    35,442

    Marketable securities

    2,016

    50

    Accounts receivable, net

    638

    745

    Prepaid expenses and other current assets

    2,554

    2,204

    Total current assets

    50,997

    38,441

    NONCURRENT ASSETS

    Property and equipment, net

    2,251

    2,245

    Operating lease right-of-use assets

    2,144

    2,522

    Deposits and other long-term assets

    614

    577

    Goodwill

    10,672

    10,672

    Intangible assets, net

    46,540

    46,562

    TOTAL ASSETS
     
    $
    113,218

    $
    101,019

    LIABILITIES AND SHAREHOLDERS’ EQUITY

    CURRENT LIABILITIES

    Accounts payable and accrued liabilities
     
    $
    5,437

    $
    6,270

    Operating lease liabilities, current portion

    1,097

    830

    Finance lease liabilities, current portion

    55

    52

    Deferred revenues, current portion

    7,388

    10,808

    Total current liabilities

    13,977

    17,960